Cargando…

Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial

Purpose: Research comparing the clinical efficacy of dexlansoprazole and esomeprazole has been limited. This study aims to compare the clinical efficacy of single doses of dexlansoprazole (modified-release 60 mg) and esomeprazole (40 mg) after 24-week follow-up in patients with mild erosive esophagi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiang, Hung-Hsien, Wu, Deng-Chyang, Hsu, Pin-I, Kuo, Chao-Hung, Tai, Wei-Chen, Yang, Shih-Cheng, Wu, Keng-Liang, Yao, Chih-Chien, Tsai, Cheng-En, Liang, Chih-Ming, Wang, Yao-Kuang, Wang, Jiunn-Wei, Huang, Chih-Fang, Chuah, Seng-Kee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499145/ https://www.ncbi.nlm.nih.gov/pubmed/31118571 http://dx.doi.org/10.2147/DDDT.S193559

Ejemplares similares

First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease
por: Liang, Chih-Ming, et al.
Publicado: (2017)

Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg
por: Kukulka, Michael, et al.
Publicado: (2011)

Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice
por: Hung, Kuo-Tung, et al.
Publicado: (2021)

A comparison between dexlansoprazole modified release–based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial
por: Tai, Wei-Chen, et al.
Publicado: (2019)

Managing gastroesophageal reflux disease – comparative efficacy and outcomes of dexlansoprazole MR
por: Frye, Jeanetta W, et al.
Publicado: (2015)

Phase 4 Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole
por: Wu, Justin C Y, et al.
Publicado: (2020)

Clinical Characteristics of Patients with Gastroesophageal Reflux Disease Refractory to Proton Pump Inhibitors and the Effects of Switching to 20 mg Esomeprazole on Reflux Symptoms and Quality of Life
por: Takeshima, Fuminao, et al.
Publicado: (2015)

Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease
por: Kukulka, Michael, et al.
Publicado: (2014)

A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD)
por: Kalaitzakis, Evangelos, et al.
Publicado: (2007)

Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule
por: Kukulka, Michael, et al.
Publicado: (2016)

Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients – focus on esomeprazole
por: Tang, Raymond SY, et al.
Publicado: (2013)

Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease
por: Bayerdörffer, Ekkehard, et al.
Publicado: (2016)

Current Pharmacological Management of Gastroesophageal Reflux Disease
por: Wang, Yao-Kuang, et al.
Publicado: (2013)

Clinical utility of esomeprazole for treatment of gastroesophageal reflux disease in pediatric and adolescent patients
por: Cardile, Sabrina, et al.
Publicado: (2012)

Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole
por: Mermelstein, Joseph, et al.
Publicado: (2016)

On-demand versus half-dose continuous therapy with esomeprazole for maintenance treatment of gastroesophageal reflux disease: A randomized comparative study
por: Cho, Joon Hyun, et al.
Publicado: (2018)

Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor – Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region
por: Goh, Khean Lee, et al.
Publicado: (2016)

Current advances in the diagnosis and management of gastroesophageal reflux disease
por: Liang, Shu-Wei, et al.
Publicado: (2022)

Correlation between Psychosomatic Assessment, Heart Rate Variability, and Refractory GERD: A Prospective Study in Patients with Acid Reflux Esophagitis
por: Wang, Hsin-Ming, et al.
Publicado: (2023)

Diagnosis and Management of Gastroesophageal Reflux Disease
por: Hsu, Ping-I, et al.
Publicado: (2013)

Gastroesophageal Reflux Disease Relief in Patients Treated with Rabeprazole 20 mg versus Omeprazole 20 mg: A Meta-Analysis
por: Xia, X. M., et al.
Publicado: (2013)

Efficacy and Safety of Esomeprazole for the Treatment of Reflux Symptoms in Patients with Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis
por: HOU, Mingxing, et al.
Publicado: (2020)

A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection
por: Wu, Deng-Chyang, et al.
Publicado: (2016)

Relationship between esomeprazole dose and timing to heartburn resolution in selected patients with gastroesophageal reflux disease
por: Orlando, Roy C, et al.
Publicado: (2010)

Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: focus on delayed-release esomeprazole
por: Guimarães, Elizabet V, et al.
Publicado: (2010)

Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan
por: Sakurai, Kouichi, et al.
Publicado: (2018)

Influence of capsaicin infusion on secondary peristalsis in patients with gastroesophageal reflux disease
por: Yi, Chih-Hsun, et al.
Publicado: (2016)

Randomized Controlled Trial Comparing the Efficacy of Sustained-Release Formula of Mosapride-Plus-Esomeprazole Combination Therapy to Esomeprazole Monotherapy in Patients with Gastroesophageal Reflux Disease
por: Jeon, Hye Kyung, et al.
Publicado: (2022)

A Randomized, Double-Blind, Active-Control, Noninferiority, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of Esomeprazole/Sodium Bicarbonate 20/800 mg in Patients with Nonerosive Gastroesophageal Reflux Disease
por: Park, Su Hyun, et al.
Publicado: (2023)

Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety
por: Maiti, Rituparna, et al.
Publicado: (2011)

Tongue diagnosis indices for gastroesophageal reflux disease: A cross-sectional, case-controlled observational study
por: Wu, Tzu-Chan, et al.
Publicado: (2020)

A Deep Learning Model for Classification of Endoscopic Gastroesophageal Reflux Disease
por: Wang, Chi-Chih, et al.
Publicado: (2021)

Atypical Symptoms in Patients With Gastroesophageal Reflux Disease
por: Yi, Chih-Hsun, et al.
Publicado: (2012)

Induced Sputum Substance P in Children with Difficult-to-Treat Bronchial Asthma and Gastroesophageal Reflux: Effect of Esomeprazole Therapy
por: Bediwy, Adel Salah, et al.
Publicado: (2011)

Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease
por: Gold, Benjamin D., et al.
Publicado: (2017)

Gastroesophageal reflux in Bronchiectasis and the effect of anti-reflux treatment
por: Hu, Zhi-Wei, et al.
Publicado: (2013)

The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations
por: Liu, Chien-Ying, et al.
Publicado: (2017)

Effect of Hydroxyapatite on the Mechanical Properties and Corrosion Behavior of Mg-Zn-Y Alloy
por: Chiu, Chun, et al.
Publicado: (2017)

Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections
por: Kuo, Chia-Jung, et al.
Publicado: (2019)

Risk factors influencing the outcome of peptic ulcer bleeding in chronic kidney disease after initial endoscopic hemostasis: A nationwide cohort study
por: Liang, Chih-Ming, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hj490ib198f1i0omvblpfsbq4u